Thornburg Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Thornburg Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,335,555	Closed	-$52.3M	–	186
2019 Q1	$52.3M	Sell	3,335,555 -203,966	-6%	-$3.6M	0.51%	56
2018 Q4	$54.6M	Sell	3,539,521 -488,671	-12%	-$10M	0.53%	50
2018 Q3	$86.8M	Buy	4,028,192 +202,777	+5%	+$4.71M	0.72%	40
2018 Q2	$93M	Buy	3,825,415 +16,888	+0.4%	+$344K	0.71%	38
2018 Q1	$65.1M	Buy	3,808,527 +1,032,302	+37%	+$20.2M	0.49%	48
2017 Q4	$52.6M	Buy	2,776,225 +1,706,406	+160%	+$25.7M	0.37%	62
2017 Q3	$18.8M	Sell	1,069,819 -3,236,898	-75%	-$72.8M	0.13%	133
2017 Q2	$143M	Buy	+4,306,717	New	+$133M	1.09%	27
2013 Q4	–	Sell	-1,541,558	Closed	-$58.2M	–	293
2013 Q3	$58.2M	Buy	1,541,558 +25,725	+2%	+$1M	0.23%	112
2013 Q2	$59.4M	Buy	+1,515,833	New	+$59M	0.27%	103

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Thornburg Investment Management's TEVA Position: Q2 2019 in Review

Thornburg Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 3,335,555 shares — an estimated $52.3M sold.

Thornburg Investment Management first reported a position in TEVA in Q2 2013 and held it in 10 quarters. The position peaked at $143M in Q2 2017. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

Thornburg Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Thornburg Investment Management sold 3,335,555 Teva Pharmaceuticals shares in Q2 2019, an estimated $52.3M.
Thornburg Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Thornburg Investment Management's Teva Pharmaceuticals position peaked at $143M in Q2 2017.
452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Thornburg Investment Management's 13F filing for Q2 2019, filed 6 Aug 2019.